Liquidia Corporation to Present at 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Liquidia (NASDAQ: LQDA) announced that CEO Dr. Roger Jeffs will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at approximately 5:15 p.m. PT / 8:15 p.m. ET at the Westin St. Francis in San Francisco.
A live, audio-only webcast will be available on the company Investors page and will be archived on the website for at least 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – LQDA
In the Jan 7 session, LQDA gained 0.88%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 03 | Conference participation | Positive | +3.5% | Announcement of November 2025 investor conference presentations and webcasts. |
| Nov 03 | Earnings update | Positive | +3.5% | Q3 2025 results highlighting YUTREPIA launch momentum and improved profitability. |
| Oct 27 | Earnings scheduling | Positive | +1.7% | Scheduled Q3 2025 results release and webcast with corporate update details. |
| Oct 07 | R&D day event | Positive | +5.1% | R&D Day announcement with updates on L606 and YUTREPIA for investors. |
| Sep 29 | Clinical data conference | Positive | +4.6% | Upcoming ASCENT trial data presentations at CHEST 2025 annual meeting. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news, especially conferences and clinical/earnings updates, has typically coincided with positive price reactions.
Over the last few months, Liquidia has reported strong commercial ramp for YUTREPIA, with Q3 2025 revenue of $54.3 million and product sales of $51.7 million, alongside multiple conference and R&D events highlighting YUTREPIA, L606 and ASCENT trial data. Prior conference-related announcements on Sep 29, Oct 7, Oct 27 and Nov 3 all saw positive 24-hour price reactions between +1.7% and +5.1%. Today’s J.P. Morgan conference appearance fits this pattern of active investor engagement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MORRISVILLE, N.C., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Dr. Roger Jeffs, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 beginning at approximately 5:15 p.m. Pacific Time (8:15 p.m. Eastern Time) at the Westin St. Francis in San Francisco, California.
Access to a live, audio-only webcast will be available on the “Investors” page of Liquidia’s website at https://liquidia.com/investors/events-and-presentations. The webcast will be archived on the company's website for at least 30 days.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases through precise, innovative therapies and applications of its proprietary PRINT® Technology. PRINT enabled the creation of Liquidia’s first approved product, YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational extended-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.
Contact Information
Investors:
Jason Adair
Chief Business Officer
919.328.4400
jason.adair@liquidia.com
Media:
Patrick Wallace
Director, Corporate Communications
919.328.4383
patrick.wallace@liquidia.com
